

China Consumer Staples

Self help and defensiveness as key; Look for a steadier 1Q25

The staple sector has risen 3% YTD in line with the MSCI China index and has remained relatively resilient in the past week (down 1% vs. MSCI China -9%) amid trade tensions. In this report, we look at the recap of 2018 in terms of subsector performance during trade tensions (*staples outperformed in the offshore market in 2018, spirits lagged in onshore market*) and discuss the potential implication to our coverage from China import tariff changes (*mainly, potential cost inflation from China import tariff hikes; while exposure to the US tariff hikes is very limited for our staple universe except for Pet Foods*). For 1Q25, we look for staples to see a steadier trend, be sequentially better vs. 4Q24 with steadier pricing/volume supported by healthier channel inventory and stabilizing pricing. We expect gradual demand recovery for beer/dairy while we see idiosyncratic topline drivers with strong SKU/new products launches for beverage/snacks/pet foods. As we enter an even lower base starting from 2Q25 we expect seasonally stronger topline growth for categories such as dairy/beer/snacks, and remain prudent on general consumption confidence/sentiment under trade tensions (*GS real GDP growth forecasts for 2025 and 2026 lowered to 4.0% and 3.5%*) while policy push for domestic demand is still key.

Potential exposures to tariff changes: Except for the Pet Foods segment (US export sales exposure is at c.17%~70%, China exports to US exposure is at c.6%~12% in 2024), we see limited impact for our staple coverage from US tariff hikes to China given very limited US exports exposure (zero to LSD%). Meanwhile, F&B names are still stepping up on practical strategies for “Going Global” including exports/supply chain/M&A potential, mostly starting with the SEA market. **Our lessons from previous trade tensions suggest that there are potential inflation risks** in soybean, nuts (mainly almonds/pistachio), and pork in China, which are key raw materials for select staples categories e.g soy sauce, frozen foods and snacks, indicating cost headwinds and inflation risks for the relevant staples products.

Recap of 2018 - Staple was defensive: The trade war back in 2018 led to significant volatility and the SSE index fell c.-25% in 2018. The US announced additional tariff plans firstly in Mar 2018, effective in July; and further tariffs were effective in Sep. We note the consumer staples sector was generally more defensive amid tariff

Leaf Liu

+852-3966-4169 | leaf.liu@gs.com
Goldman Sachs (Asia) L.L.C.

Valerie Zhou

+852-2978-0820 | valerie.zhou@gs.com
Goldman Sachs (Asia) L.L.C.

Hongda Zhong

+852-2978-2300 |
hongda.zhong@gs.com
Goldman Sachs (Asia) L.L.C.

Julia Mu

+852-2978-1219 | julia.mu@gs.com
Goldman Sachs (Asia) L.L.C.

Christina Liu

+852-2978-6983 | christina.liu@gs.com
Goldman Sachs (Asia) L.L.C.

uncertainties (down -11%/-20% offshore/onshore), in which condiments, pet care and frozen foods delivered solid positive returns in 2018. Spirits saw the largest drawdown in 2018 but mostly from P/E multiple de-ratings instead of downward earnings revisions.

Key focuses in 1Q25/2025: We favor margin enablers with self-help operating efficiency measures and cost tailwinds (see our latest cost tracker) for Mengniu/Tingyi/CR Beverage/Beer, while we also like names with solid topline growth momentum with new product in rising cycles including Eastroc (*strong trend in electrolyte water with recently launched fruity tea ramping up*), Yanker (Konjac SKU on *strong momentum*) and Pet Foods (*solid GMV growth for Gambol at 51% yoy in Mar*). Meanwhile, most staples companies have further highlighted their commitment to improving FCF and shareholder returns over the next few years, including more attention to buybacks (Moutai).

- **1Q Run-rate vs. full year: China brewers** mostly saw sequential recovery in 1Q with positive volume growth, running ahead of conservative full-year expectation of industry volume declines; **Beverages** basically presented an encouraging trend ahead of our full-year expectation, where UPC is running ahead at DD% sales growth in Jan/Feb, Eastroc 1Q sales up 39% with continued strong momentum supported by new product launches and Nongfu ramping up since March on a low base, and **dairy** demand recovery is also expected to come in 2Q25 (Yili UHT milk turning positive in March). **For China spirits**, players faced a tough comp and focused on destocking amid still muted commercial demand; we look for -15% to +10% sales trend in 1Q25 and for a more back-end loaded demand recovery into 2H25. Pet foods strong 1Q run rate continued with solid domestic demand growth, and could benefit from front-loaded exports. Snacks growth saw wide divergence with Yanker outperforming.

We reiterate our sub-sector preferences: We continue to rank Beverage (secular growth) and Dairy (S-D rebalancing/demand bottoming out/potential policy beneficiary, and upgraded Feihe) as our most preferred; followed by Beer/Pet foods (penetration). Our key stocks are Moutai/Mengniu/Tsingtao-H/CR Beer/CR Beverage/Feihe/Tingyi/Eastroc/China Pet Foods (all Buy rated). *We update estimates and price targets for select companies within.*

Relevant reports:

China Consumer Staples Cost Index Tracker: Mar 2025: Divergent protein prices; palm oil to ease; Pet/prepared meal up sequentially

China Feihe Ltd. (6186.HK): Market share gainer with strong execution amid steadier industry outlook; upgrade to Buy

China Consumer Staples: 4Q24 Preview: Looking for a better start into 2025 after a reset in 4Q24; Watch out for policy roll-out

2024/1Q25 Results Preview summary

Exhibit 1: 4Q24/1Q25 preview summary table

Ticker	Company	4Q24E/A				1Q25E/A				2024E/A				2025E				2026E			
		Sales	Sales yoy	Net profit	NP yoy	Sales	Sales yoy	Net profit	NP yoy	Sales	Sales yoy	Net profit	NP yoy	Sales	Sales yoy	Net profit	NP yoy	Sales	Sales yoy	Net profit	NP yoy
Spirits																					
600519.SS	Kweichow Moutai*	51,022	13%	25,401	16%	50,901	10%	26,442	10%	174,144	16%	86,228	15%	188,453	9%	94,978	10%	206,702	9%	104,681	10%
000858.SZ	Wuliangye Yibin	18,717	-10%	6,304	-15%	36,575	5%	14,683	5%	86,632	4%	31,235	3%	91,422	8%	33,284	7%	98,642	8%	36,434	9%
000561.SZ	Shantui Shuang Fen Wine	1,777	-3%	1,202	-20%	1,864	-30%	9,188	0%	4,552	0%	30,561	-1%	13,457	10%	31,218	2%	14,038	4%	33,573	8%
000660.SZ	Lushou Leigong	6,257	-25%	1,884	-30%	9,188	0%	4,552	0%	30,561	-1%	29,288	-21%	7,743	-23%	29,032	-1%	7,727	0%	20,885	3%
000596.SZ	Jiangsu Yanghe	1,771	-38%	(836)	n.m.	13,817	-15%	4,811	-21%	23,577	16%	5,514	20%	25,960	10%	6,139	11%	28,243	9%	6,805	11%
000779.SS	Anhui Gujing Distillery Co.	4,509	5%	768	11%	8,949	8%	2,249	9%	1,429	5%	216	12%	5,217	5%	1,341	6%	5,461	5%	5,814	6%
603369.SS	Sichuan Sifutun Co.*	1,429	5%	216	-12%	933	0%	182	-1%	1,842	6%	514	3%	11,784	17%	3,600	15%	12,786	9%	3,933	9%
603369.SS	Jiangsu King's Luck Brewery	1,842	6%	514	3%	5,044	8%	1,660	8%	1,842	6%	514	3%	11,784	17%	3,600	15%	12,786	9%	3,933	9%
Weighted Avg.	Super premium spirits	2%	5%	7%	7%	10%	10%	11%	11%	7%	9%	9%	10%	6%	6%	8%	8%	10%	10%	10%	10%
Weighted Avg.	Non super premium spirits	-10%	-41%	0%	-3%	4%	1%	6%													
Brewer																					
600600.SS	Tsingtao Brewery	3,179	7%	(645)	n.m.	10,455	3%	1,713	7%	32,138	-5%	4,345	2%	33,416	4%	4,882	12%	34,620	4%	5,378	10%
000132.SS	Chongqing Brewery*	1,582	-11%	(217)	n.m.	4,352	1%	460	1%	14,645	-1%	1,115	-17%	15,082	3%	1,341	20%	15,582	3%	1,454	8%
000568.SZ	Shanghai Baiven	609	-25%	120	-17%	762	-5%	168	-1%	2,995	-8%	694	-14%	3,436	15%	849	22%	3,816	11%	972	15%
1876.HK	Budweiser APAC*	1,142	-12%	(16)	n.m.	1,494	-9%	245	-15%	6,246	-9%	726	-15%	6,402	3%	797	10%	6,741	5%	923	16%
Weighted Avg.	APAC	-9%	-28%	1%	-1%	1%	-4%	-8%	3%	1%	13%	4%	13%								
Condiments																					
600872.SS	Jonjee Hi-Tech*	1,573	33%	317	n.m.	1,410	-5%	226	-5%	5,519	7%	893	70%	5,365	-3%	796	-11%	5,846	9%	919	16%
002507.SZ	Fuling Zhaaci*	425	-15%	129	-23%	786	5%	287	6%	2,387	-3%	799	-3%	2,539	6%	864	8%	2,686	6%	920	7%
600905.SS	Jiangsu Hengshun Vinegar	515	10%	27	n.m.	516	12%	45	-19%	2,046	-3%	147	60%	2,209	8%	199	35%	2,473	12%	245	23%
603317.SS	Sichuan Teway Food Group*	1,112	22%	192	41%	896	5%	180	2%	3,476	10%	625	37%	3,736	7%	693	11%	3,986	7%	772	11%
Weighted Avg.	Food Group	15%	22%	7%	8%	8%	8%	9%													
Dairy																					
600887.SS	Yili Industrial	27,412	-5%	1,268	14%	31,652	-3%	3,659	-2%	116,452	-8%	9,777	-2%	119,998	3%	10,845	11%	123,084	3%	11,838	9%
Weighted Avg.	Dairy	-5%	14%	14%	2%	3%	3%	2%	3%	2%											
Beverage																					
605499.SS	Eastroc**	3,281	25%	619	61%	4,848	39%	980	48%	15,839	41%	3,327	63%	20,350	28%	4,459	34%	24,556	21%	5,531	24%
Snacks																					
002667.SZ	Chacha Food Co.*	2,374	2%	238	22%	1,602	7%	164	36%	7,123	6%	864	6%	7,514	6%	826	2%	7,043	6%	944	13%
002847.SZ	Yankeeshop Food	1,459	31%	156	42%	1,412	15%	171	7%	5,319	29%	649	28%	6,369	20%	808	24%	7,337	15%	922	14%
300783.SZ	Three Squirrels	3,453	36%	67	33%	4,375	20%	294	-5%	10,622	49%	408	8%	14,149	33%	454	11%	17,864	26%	601	32%
Weighted Avg.	Food Group	11%	4%	6%	6%	1%	12%	10%	10%	11%	2%	11%	6%	10%	9%	10%	9%	11%	6%	17%	6%
Pet Care																					
002891.SZ	China Pet Foods*	1,278	24%	98	74%	994	13%	85	50%	4,467	19%	380	63%	5,018	12%	423	11%	5,777	15%	558	32%
301498.SZ	Gambol Pet Group	1,510	24%	147	28%	1,307	10%	178	20%	5,181	20%	617	44%	6,203	20%	755	22%	7,423	20%	947	25%
300673.SZ	Petpal Pet Nutrition Technology*	511	3%	33	81%	423	10%	49	19%	1,834	30%	187	n.m.	2,223	21%	200	7%	2,617	18%	255	28%
Weighted Avg.	Pet Care	20%	47%	15%	27%	21%	21%	17%	17%	17%	1%										
H share	Company	2H24A																			
		2H25E																			
		2024A																			
		2025E																			
		2026E																			
1579.HK	Yihai International Holding	3,613	2%	431	-13%	3,110	6%	341	10%	6,540	6%	739	-13%	7,071	8%	859	15%	7,522	6%	941	11%
2219.HK	Mengniu Dairy*	4,004	-7%	2,668	47%	43,808	-2%	2,417	11%	8,872	-10%	5,602	13%	30,101	1%	5,644	4%	30,115	4%	6,380	9%
6193.HK	China Milk Ltd.	10,654	9%	1,973	-3%	10,553	7%	2,302	20%	20,149	4%	1,185	22%	22,272	7%	7,655	14%	19,401	5%	5,060	8%
9633.HK	Nongfu Spring	20,723	-7%	5,863	9%	25,039	13%	6,768	9%	42,896	1%	12,083	0%	49,065	14%	13,616	13%	55,397	13%	15,187	12%
0322.HK	Tinyi	39,450	0%	1,849	25%	42,796	4%	2,196	16%	80,651	0%	3,734	20%	83,836	4%	4,332	16%	86,306	3%	9,938	14%
0220.HK	Uni-President China*	14,883	6%	883	12%	16,692	8%	1,121	16%	30,332	6%	1,849	11%	32,305	7%	2,111	14%	33,853	5%	2,334	11%
2460.HK	CR Beverage	5,905	n.m.	42	n.m.	8,082	6%	1,468	21%	13,521	0%	1,637	23%	14,607	8%	2,063	26%	15,819	8%	2,421	17%
0151.HK	Want Want China	12,401	1%	2,115	-6%	11,198	3%	1,986	7%	23,338	0%	3,979	4%	23,662	1%	3,933	-1%	24,274	3%	3,949	0%
0291.HK	China Resources Beer	14,891	-1%	34	-93%	24,010	1%	4,964	6%	38,635	-1%	4,739	-8%	39,421	2%	5,258	11%	40,209	2%	5,853	11%
6979.HK	ZJLD	2,934	-16%	688	-20%	3,389	-18%	804	-21%	7,067	1%	1,676	3%	6,730	-5%	1,638	-2%	7,359	9%	1,831	12%

*denotes companies that have reported actual results for 4Q24/FY24. **denotes companies that have reported 1Q25. Want Want is using calendar year data. Chongqing recurring NP growth at 10% in 2025E.

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 2: Summary of sub-sector quarterly growth in consumer staple space (market-cap weighted)

Sector	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24/A/E	1Q25E	2Q25E
Frozen food	16.5%	29.0%	36.4%	26.4%	50.2%	21.3%	24.7%	24.4%	15.5%	26.2%	18.5%	17.0%	24.3%	19.3%	14.4%	-6.0%	9.2%	-1.1%	-0.1%	6.0%	8.3%	8.2%
Beer	-30.6%	-3.1%	2.4%	3.6%	56.0%	7.4%	2.2%	9														

Recap of 2018 - Staple index performance relatively more resilient in 2018 trade tensions


Recap of 2018

We look back at the performance of different staple sub-sectors during the last period of heightened trade tensions in 2018 given the recent increase in US and China tariffs.

The trade war back in 2018 led to significant volatility in China's financial markets, where the SSE index fell c.-25% in 2018. The US announced additional tariff plans firstly in Mar 2018, effective in July; and further tariffs were effected in Sep. We noted the consumer staples sector was generally more defensive amid tariff uncertainties (down -11%/-20% offshore/onshore), in which condiments, pet care and frozen foods delivered solid positive returns in 2018. Spirits saw the largest drawdown in 2018 but mostly from P/E multiple de-ratings instead of downward earnings revisions.


Interestingly, we saw a sharp rebound in 2019 in the spirits sector likely due to policy easing, and a rebound in sentiment, while the condiment and beer sectors also outperformed in 2019 following their resilience in 2018.

Exhibit 3: Pet care and condiments names under our coverage outperformed in 2018 across the consumer staples universe; spirits saw the largest drawdown in 2018 followed by the sharpest rebound in 2019



Source: Refinitiv Eikon


Exhibit 4: Condiment names outperformed while spirits/beer names underperformed across our consumer staples universe; the share price changes were mainly due to P/E multiple revisions for most companies



Source: Refinitiv Eikon

Recap of 2018 performance by style/sector

Consumer staples was relatively stable



Source: Bloomberg, FactSet, Wind, Goldman Sachs Global Investment Research

MSCI China constituents best and worst performers in 2018

	A			HK			ADR		
	Ticker	Name	Return	Ticker	Name	Return	Ticker	Name	Return
Top 5 performer	600436 CG	Pientzhuang Pharma	45%	1579 HK	Yihai International	169%	ATHM UN	Autohome	39%
	600588 CG	Yonyou Network Tech	42%	612 HK	China Ding Yi Feng	166%	GDS UQ	GDS	17%
	601888 CG	China Int'l Travel Service	40%	2768 HK	Jiayuan International	86%	BZUN UW	Baozun	17%
	603288 CG	Foshan Haitian Flavouring	29%	241 HK	Alibaba Health	76%	JOBS UW	51job	12%
	600027 CG	Huadian Power Int'l	27%	268 HK	Kingdee Int'l Software	75%	MOMO UW	Momo	4%
Bottom 5 performers	000839 CS	CITIC Guoan	-63%	1357 HK	Meitu	-78%	VIPS UN	Vipshop	-52%
	002241 CS	GoerTek	-59%	1114 HK	Brilliance China	-70%	JD UW	JD.com	-45%
	600816 CG	Anxin Trust	-55%	2018 HK	AAC Technologies	-65%	YY UW	YY	-42%
	000826 CS	Tus-Sound Environmental	-54%	2799 HK	Huarong Asset Management	-59%	EDU UN	New Oriental Education	-40%
	002508 CS	Robam Appliances	-53%	867 HK	China Medical System	-59%	WB UW	Weibo	-38%


Source: FactSet

This round there is more support from shareholder returns in the staple space

Dividend yield has become a key focus of investors in recent quarters (dividend yield plays outperformed in 2018). Our staples coverage has more names with attractive dividend yields, which we think serve as a cushion to share price volatility.

Exhibit 5: We note the dividend yield of China consumer staples continued to be higher than the 10-year bond yield and China avg. dividend yield in 2025

Yield gaps



Source: MSCI, Refinitiv Eikon, Goldman Sachs Global Investment Research

Exhibit 6: Summary of consumer staples coverage stocks with dividend yield >4%

Company name	Dividend payout ratio		Dividend yield		FCF yield		FCF as % of sales		Net cash to equity	
	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025
High dividend yield (>4%)										
Jiangsu Yanghe	91%	91%	6.5%	6.4%	7.7%	7.1%	29%	27%	54%	57%
Yihai International	89%	89%	5.5%	6.2%	3.7%	7.8%	7%	13%	45%	49%
Tingyi	100%	100%	5.2%	6.0%	6.4%	7.2%	6%	6%	-34%	-24%
UPC	100%	100%	5.1%	5.7%	10.0%	5.9%	12%	7%	23%	25%
Feihe	64%	65%	5.1%	5.7%	3.9%	7.9%	10%	19%	30%	37%
Want Want China	77%	80%	5.5%	5.6%	7.7%	7.3%	18%	17%	22%	27%
Budweiser APAC	97%	91%	5.1%	5.2%	5.1%	7.2%	12%	17%	26%	29%
Chongqing Brewery	104%	100%	4.1%	4.7%	5.2%	10.4%	10%	20%	42%	74%
Wuliangye Yibin	70%	70%	4.4%	4.6%	6.4%	7.0%	37%	39%	90%	93%
Tsingtao-H	69%	68%	4.1%	4.5%	3.4%	5.0%	8%	11%	60%	58%
Luzhou Laojiao	60%	60%	4.3%	4.4%	6.9%	7.0%	42%	43%	42%	48%
Yili Industrial	73%	73%	3.9%	4.2%	6.6%	6.7%	10%	11%	-11%	-2%

Blue highlights denote Buy-rated stocks

Source: Company data, Goldman Sachs Global Investment Research

1Q25/2025: Self-help measures and cost tailwind to help margin resilience; Prudent sales outlook mainly on sequential recovery while beverage/snacks seeing upside from product cycle

#1: Margin enablers: self-help and cost tailwinds to drive earnings visibility, while investment level showing a mixed trend

Operating efficiency and spending control: Coming out of 2024, we noted an acceleration in streamlined overheads/headcount in some sectors (ie. beer/dairy/condiments) and more focus on an evaluation of commercial investment returns and operating efficiency. We think opex control will remain as a key focus amid a gradual recovery in topline growth into 1Q/1H25, while the human resource optimization

which was mostly done in 2H24 will continue to help earnings visibility.

Cost tailwinds: Based on our latest cost tracker, we still expect most staples players to see cost tailwinds yoy in 2025, incl. compound condiments, pet food, dairy, prepared meal, beverage, soy sauce, frozen flour and rice. In 1Q25, many key materials e.g. chicken/PET/raw milk/glass/paper pulp are still in a declining trend by -25%/-10%/-14%/-5%/-2% in terms of spot prices yoy. Also, most brewers have locked in MSD to HSD% cost reduction in barley sourcing for 2025, adding visibility for the cost trend in 2025.

Investment level: While the priority is still margin resilience, we heard mixed messages on investment level. In dairy, Mengniu is looking for a steady core OPM in 2025 post a strong OPM beat in 2024 (up c. 200bps) with more focus on investment for market share gain amid a reconsolidation in the dairy market as the S/D gradually rebalances. In beer, CR Beer and Chongqing are more disciplined in their investment level while Bud has shifted focus to volume share. In condiments, Yihai highlighted continued investment for 2B/lower tier penetration post a high investment for online sales in 2024 and is focusing more on topline growth in 2025. We think staple companies will partially re-invest the cost benefits to position for a topline recovery in 2025 post channel destocking in 2024.

Exhibit 7: Many staples subsectors saw employee reductions in 2023/24, esp. beer, dairy

Number of total employees - YoY changes


YoY changes in the total number of employees	2020	2021	2022	2023	2024
Sub-sector average	5%	6%	9%	4%	
Spirits	-5%	31%	-2%	0%	-8%
Beer	12%	5%	5%	2%	0%
Condiment	12%	12%	7%	-2%	-4%
Dairy	8%	9%	1%	4%	3%
F&B	14%	-1%	-7%	-1%	15%
Snacks	10%	20%	4%	5%	
Frozen Foods	27%	3%	-4%	-1%	
Pet Care					

2024 only includes companies that have released annual results

Source: Company data, Wind

Exhibit 8: Sector cost index vs. 2023, 2024, avg. 2024

Feb 2025



Source: Wind, Bloomberg, Goldman Sachs Global Investment Research

#2: Prudent sales growth outlook in staple space mainly on sequential recovery, while brighter outlook mainly from beverage/snacks/pet foods on core/new product cycle

Prudent sales growth outlook in staple space mainly on sequential recovery: We are observing a wider divergence in the staples sub-sector outlook due to different impacts from the macro /S-D cycles. **Beer:** LSD volume growth expected by many **brewers** post a weak 2024, with off-trade supporting growth but still very cautious ASP outlook given that on-trade weakness still lingering in the near-term. **Dairy:** players look for better performance vs. 2024 with a more balanced supply/demand dynamic into 2H25 but also still prudently look for largely flattish to minor growth in the liquid milk segment in 2025 (we look for a decline in the liquid milk segment in 1Q25 but expect a low base to help from 2Q25). **Traditional F&B:** also aims at improving topline, while fast-growing **beverage players** expect some growth normalization but new product launches remain with upside potential. While we expect a sequential recovery for dairy/beer, and product upcycle for beverage/snacks, **China spirits** companies look for more conservative growth in 2025 under macro headwinds and continued focus on channel inventory destocking, with most companies looking for a slower growth in 2025 vs. 2024 and more back-ended growth in 2025 (e.g Moutai at c.9% yoy for 2025 vs. 15% guided for 2024).

Brighter outlook mainly from beverage/snacks/pet foods on new product cycle: In the F&B space, we have noted several encouraging launches for major SKU in the past few years e.g Danhuang for Yanker (quail egg) in 2024, and Bushuila for Eastroc (functional sports beverage) in 2023. We see the new product launches likely to

continue to drive topline growth for beverage/snacks in 2025, where the success seen in Eastroc's Fruity tea (Guozhicha) SKU launched in early 2025, and Yanker's encouraging run rate for Konjac related products in 2025YTD. While we expect competition intensity will not fade in growing consumer sectors, we believe our covered leading players could still gain shares through strong channel execution (greater penetration to existing distribution/channel networks) and compelling product innovation capability with dedicated brand cultivation. **In 2025 YTD:** We note the solid run-rate for beverage/snacks, with UPC beverage/Eastroc/CR Bev sales up DD% yoy, Tingyi beverage up +SD% yoy, and Nongfu re-accelerated since March lapping an easier comp base. For snacks, we note a strong run rate for Yanker with 15%+ yoy growth in 1Q on GSe, supported by fast major SKU ramp up while other snack brands continue to face headwinds on tough base and channel shift drag. **However, pricing competition persists for large-pack launch:** Brands are leveraging large packs to offer value-for-money options for the existing products (eg Nongfu, Eastroc, Three Squirrels, Wahaha etc), and we also note growing new entrants into food and beverage, including Three Squirrels into beverage, and retailers such as discounters and KA.

Strong run rate for key SKUs and new SKU launches:

- **Eastroc:** Eastroc reported 1Q25 results with a 39% yoy sales growth, and strong momentum in both energy and non-energy drinks. Following the footprint of its hyper growth product electrolyte water Bushuila (growing at 280% yoy in 2024, total electrolyte water accounted for 12% of total 1Q25 sales vs. 5% in 1Q24), Eastroc launched Guozhicha, a large-pack sweetened tea providing great value-for-money. We think a fast roll-out in POS coverage can be an initial indicator for the success of a SKU, e.g Guozhicha now covers c.800k POS (roughly 20% of Eastroc's total POS) within 1 month of launching. We estimate a 2% sales contribution from overall tea sales (including Guozhicha) in 2025 at Rmb500mn from c. Rmb130mn in 2024.
- **Nongfu:** We note Nongfu has added new flavors to its Oriental Leaf/NFC juice portfolio and large-pack sugar-free tea catering to evolving customer preferences, and we expect this to support our expectation of 26%/10% yoy sales growth for tea/juice in 2025E. According to Euromonitor, Nongfu's 100% juice recorded Rmb1.4bn retail sales in 2024, accounting for 10%+ market share in the 100% juice market and it is the #2 player.
- **CR Beverage:** while its margin expansion is on track, it is also working on category expansion with new product launches in 2025 spanning multiple categories - special water packages for sports scenarios, new flavors for its juice series, and new RTD coffee brand Yan Baked, fueling the c.37% yoy growth in beverage in 2025E on GSe (we estimate sales contribution of beverages climbing to 13% in 2025 vs. 10% in 2024).
- **Yankershop:** We expect close to 30% of sales are Konjac or quail eggs related which will likely deliver 30%~50%+ yoy sales growth for 2025E per GSe. The company also launched a new product series/subcategory called Tiger Skin Pattern Triplets with dried tofu product, to capture the plant-based protein trend. It has already received 15mn+ views on social media for its first blockbuster product tiger-skin pattern fish tofu.

■ **Gambol/China Pet Foods:** We continue to see our covered companies' strength in innovative products, where Myfoodie/Fregate/Wanpy are all introducing higher-end new concept products (e.g. Goat Milk/Gold Shield in Myfoodie/Wanpy, in the note [exhibit 16](#)) to drive brand momentum, on top of faster new client acquisition, healthy repurchase rates and disciplined promotion costs tracked in Douyin. We see ongoing strong GMV growth for Gambol at 51% yoy in Mar (thanks to Fregate brand's strong, ongoing growth momentum of 106% yoy in Mar), leading its 1Q25 at 50% yoy faster than 2024's average of 40% yoy. China Pet Foods has accelerated in both Douyin and Tmall channels, which we attribute to the enhanced brand image from appearing in CCTV's factory livestreaming event during the "3.15" World Consumer Rights Day, which highlighted the clean/safe production environment and enhanced consumers' trust in the brand.

Exhibit 9: Production Volume CAGR vs. 2019 - dairy, soft drinks, beer, spirits





Exhibit 10: Summary of new fast-growing F&B products

Key new products in 2024/2025		
Products	Launch date	Category
Eastroc		
Guozhicha (Fruity tea)	Feb-25	RTD tea
Bushuila	Jan-23	Functional drinks
Bairun		
Whisky	Nov-24	Spirits
Tingyi		
Chadecuanren	May-24	RTD tea (sugar-free tea)
Yankershop		
Danhuang	Mar-24	Snacks
CR Bev		
Zhibenqingrun Series	Aug-21	RTD tea


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 11: Oriental Leaf has primarily supported the topline growth of Nongfu since 2023




Source: Company data, Goldman Sachs Global Investment Research

Exhibit 12: CR Bev's herbal based tea will be one of the key growth drivers in our model




Source: Company data, Goldman Sachs Global Investment Research

Exhibit 14: Bushuila has rapidly penetrated Eastroc's existing POS network by 50%+ within 15 months of launching




Source: Company data, Goldman Sachs Global Investment Research

Exhibit 13: We expect Bushuila to grow as another sales pillar for Eastroc, which previously was a single-growth-engine company



Source: Company data, Goldman Sachs Global Investment Research

Exhibit 15: We expect Bairun's Whisky business to become a key pillar of its sales growth ahead



Source: Company data, Goldman Sachs Global Investment Research

2024 Wrap Up

As of Apr 16, 21 of our covered companies have reported 4Q24/FY24 results (2 spirits, all 4 beer, 6 condiments, 5 F&B, 2 dairy, 1 snack, 2 prepared foods) - which have generally been in line with GSe/preliminary results. While staple companies focused on inventory digestion and margin enablers in 2024/4Q24, the outlook generally pointed to 2025YTD growth run-rate also being generally better than 2024 or in line with managements' expectations (echoing our [4Q24 results preview](#)).

1- Self-help measures + cost benefits as major margin enablers: Operating efficiency and spending control: In 2024 results, we noted many companies, incl. CR Bev, Mengniu, CR Beer, Tingyi, have prioritized the ROI assessment of the selling expenses (e.g A&P) or streamlined the overheads/headcount, as well as the importance of an evaluation of commercial investment returns and operating efficiency. We think opex control will remain as a key focus amid a gradual recovery in topline growth into 1Q/1H25, while the efficiency measures will continue to be executed for 2025.

2- Topline still weak/declined for most categories except for beverage/snacks:

Recap of volume/ASP trend in 4Q24: Based on our observations across the names

that have reported, for **volume trends** of spirits/beer/dairy/diversified F&B names, we observed some shipments were skewed more toward 1Q25 sales, and 4Q sell-in volume was relatively muted (also due to slack seasons despite an earlier LNY) for the due to channel destocking (e.g flagged by Bud APAC/ ZJLD etc). Brewers' volume run-rates in 4Q were unexciting (except Tsingtao lapping an easier base) amid channel destocking, while trending mildly better in 1Q25 (except Bud amid channel mix overhang). Dairy, especially UHT milk, continued to decline in 4Q/2H24 due to weak demand and lower pricing under oversupply, but raw milk S/D gradually improved in 2H24. Snacks faced tailwinds from an early LNY with early shipment benefiting Dec 2024/4Q24. Beverage **ASP trends** were more normalized across beverage players e.g Nongfu/CR Bev amid normalizing competition; however, ASP was under pressure in 4Q24 for brewers/ spirits companies as premiumization slowed down amid unfavorable channel/ product mix in the near-term as well as deflation. Meanwhile, the upward ASP trend was still observed for F&B players like Tingyi, which focused on pricing strategy throughout the past two years, and the promotion level was also reduced across Tingyi/UPC products.


Potential exposures to tariff changes; Implications for coverage

Very limited exposure to US tariff hike to China exports; still applying practical strategies to "Going Global"

Except for the Pet Foods segment (US exports sales exposure at c.17%~70%, China exports to US exposure is at c.6%~12% in 2024), we see very limited impact on US tariff hikes to China given very limited US exports exposure (zero to LSD%) for our staple coverage.

As we discussed in our 2025 outlook report, white space with overseas expansion is emerging as a new TAM and F&B names are stepping up on exports/supply chain/M&A potential, mostly starting with the SEA market. In the March results season, we have observed more companies discussing active strategies of going global. For example, Mengniu also highlighted their overseas expansion strategies exemplified by its solid progress in Aice in SEA. Eastroc filed for HK listing on 3 Apr and it also announced it will establish overseas footprints in Indonesia (dated Mar 2025). Feihe intends to explore market opportunities in countries with higher birth rates (e.g SEA), and has also been building its factory and overseas brand in Canada to support future IMF business in North America (entered Wal-Mart stores in Canada).

In short, we see staples companies are allocating more resources towards overseas exploration, and this time we note the business model is more L-T growth oriented, incl. building local teams, setting up factories and supply chains, and securing local distributors, vs. traditionally exporting products only.

Exhibit 16: Apparel/footwear OEM and home appliances have the highest exposure to the US market


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 17: Summary of overseas footprints of select covered staples companies

	Overseas Revenue %	Exports	Supply Chain build up	M&A	Comments
Yihai	c.5%	Y	Y		Thailand factory with 15k tons capacity in hot-pot condiments and compound condiments combined
Mengniu	c.50% of ice cream in 2024E		Y	Y	Aice in South East Asia retains strong momentum with top 1 market shares in Indonesia and top 2 in the Philippines.
Yili	c.5%	Y	Y	Y	Sales grew at DD% yoy in 2023, operating in markets incl. Southeast Asia, Africa and North America, incl ice-cream, milk, butter, etc.
Feihe	n.a.	Y	Y		Exploring market opportunities in countries with higher birth rates (e.g SEA), and also building its factory in Canada to support future IMF business in the North America
Eastroc	n.a.		Y	Potential	Dec 2024, Eastroc announced the plan of setting up a subsidiary in Indonesia with total investment up to US\$200mn, previously mainly leveraged export distributors
Wuliangye	n.a.	Y			1) Develop region-specific products to align with local consumption preferences; 2) Establish subsidiaries in 5-6 key markets; 3) Set clear incremental targets
Chacha	8.5% (1H24)	Y	Y		Chacha still enjoys product/channel expansion potential, with 90%+ of its overseas sales generated from sunflower seeds (FY23)
Want Want	HSD% (1HFY24)	Y	Y		Sales grew at mid-to-high DD% yoy in FY23; factory in Vietnam with capacity sufficient to support c. US\$100mn sales p.a., potentially expanding

Overseas revenue estimate as of 2023/2024 unless otherwise specified. Data as of end-2024.

Source: Company data, Goldman Sachs Global Investment Research

Potential exposures to import tariff changes from China to US

Our lessons from previous trade tensions suggest that there are potential inflation risks in soybean, nuts (mainly Almonds/Pistachio), and pork in China, which are key raw materials for select staples categories e.g soy sauce, frozen foods and snacks, indicating cost headwinds and inflation risks for relevant staples products. Looking back to the 2018-2019 period, the China government imposed multiple retaliatory tariffs for US goods, including but not limited to consumer/agricultural goods like **soybean, pork, corn** in response to the US' additional tariffs. We summarize key categories/products that have higher import reliance below ([Exhibit 18](#)). The heightened tariff rates for corn and soybean led to higher production costs for domestic suppliers, and based on our cost tracker, the price of corn/ soybean rose by 34%/18% from 1Q18 to 4Q20. We also performed margin sensitivity test on soy sauce players in the case of soy bean price

inflation.

On the tailwind side, we note higher tariffs for imported products such as IMF, pet food, and whisky could also be favourable for domestic players in terms of their pricing edge, while the extent of it could be limited given low imports/US imports mix.

Exhibit 18: Summary of China's reliance on US/ overall imports for selected Staples related categories

Selected staple related categories	% imported from US 2023/24	% imported mix 2023/24
Imported products		
Pet foods	c.80%	teens%
Whisky	11%	60%
Brandy	n.m.	>90%
Vermouth (Small pack)	n.m.	n.m.
IMF	<1%	20%
Wine	4%	60%
Beer	n.m.	c.2%
Imported raw materials		
Soybean	24%	83%
Barley	n.m.	80-90%
Whey	47%	>95%
Corn	26%	<5%
Pork	~7%	<10%
Almonds	55%	c.90%
Pistachio	87%	c.100%

% imported from the US refers to the % of imports from the US vs. total imports; % imported mix refers to total imports as % of total consumption in China.


Source: Euromonitor, Goldman Sachs Global Investment Research

Exhibit 19: Almonds and Pistachios are more reliant on US imports vs. others

Category	Global supply (metric tons)	China supply (metric tons)	China supply % global	China supply growth yoy	Import price (Rmb/kg)	Export price	Import vs. export	Comments on Three squirrels supply chain	US % of total import
Walnuts	1,139,080	594,000	52%	-4%	58.8	28.5	107%	Directly sourced from Xinjiang	Largest importer but small quantity only to supply niche domestic markets
Almonds	1,541,821	15,000	1%	-14%	37.8	36.3	4%		55%
Cashews	1,095,030	n.a.	n.a.	n.a.	39.4	44.6	-12%		90% from Vietnam
Pistachio	741,360	600	0%	-50%	45.2	88.5	-49%	Collaboration with Wonderful (US supplier)	87%
Pecan	164,656	2,100	1%	5%				Collaboration with Easterlin (US supplier); also directly source from Anhui, Jiangsu	Sharp value decline post geopolitical tensions by 82% yoy, small export value left at US\$10mn
Macadamia nuts	78,415	15,600	20%	n.a.	57.8	85.9	-33%	Collaboration with Golden, also directly source from Guangxi/Yunnan	3%

All kernel basis except for Pistachio (in shell). Data as of 2024 (Macadamia/Pecan as of 2023).

Source: INC, Wind, Goldman Sachs Global Investment Research

Exhibit 20: Nuts prices up 15% yoy in Dec 2024

Nut prices is the average of 5 selected nuts category import prices.

Source: Wind, Goldman Sachs Global Investment Research

Exhibit 22: US and Brazilian soybean prices diverged when China announced a 25% tariff on US soybean in 2018

Source: Bloomberg

Monthly Tracker by Sub Sector

Exhibit 24: Monthly volume table 2024-2025 based on GSe

Beer	Jan	Feb	Mar	Apr	May	2024E Beer companies' volume change yoy				Sep	Oct	Nov	Dec	2025E		
						Jun	Jul	Aug	Jan					Feb	March	
CRB	up c.9%	roughly flattish	down HSD%	down LSD%	down LSD%	down LSD%	down LSD%	down c.LSD%	positive growth	positive growth	flattish to minor growth	likely flattish	CRB	up MSD%	positive growth	
Bud APAC China	total volume under pressure while Premium continued growth, but SP declined.	total volume decline, with SP down on a high base	decline	down LSD-MSD%	down HSD%-~10%	down DD%	down HSD%	down Mid-High teens-%	down low teens-%	down DD%	down DD%	Bud APAC China	down MSD%	decline		
Tsingtao	up c.1%	down high teens%	down HSD%	down LSD%	down MSD-HSD%	down DD%	down LSD%	down HSD%	up LSD%	up MSD%	up Mid-teens-%	Tsingtao	down MSD%	up MSD%	up DD%	
Chongqing	likely up mid-to-high single digit % on low base	moderation in growth mom	decline	flat	slightly decline LSD%	flat to slight growth	down SD%	down SD%	down low SD%	Down LSD%	down SD%	decline	Chongqing	positive growth	up LSD%	
Industry	12.10%	-6.50%	-9.10%	-4.50%	-1.70%	-10.00%	-3.30%	1.40%	-2.30%	5.70%	12.20%	Industry	-4.90%			

Source: Channel checks, Goldman Sachs Global Investment Research

Exhibit 21: Overall the domestic soybean price trend follows that quoted in the US

Source: Wind

Exhibit 23: Tariff scenarios on soybean cost could lead to up to a 13pp GPM impact on Jonjee for 2025E, assuming no changes in Jonjee ASP

Soy bean tariff impact on soy sauce players' GPM	Soy bean price changes yoy	Raw material price changes on 2025E GPM yoy	Jonjee
Current YTD avg. vs. 2024 avg	-6%	1.7pp	
Additional tariff of 20%	13%	(1.2pp)	
Additional tariff of 34%	26%	(3.2pp)	
Additional tariff of 50%	41%	(5.5pp)	
Additional tariff of 84%	73%	(10.4pp)	
Additional tariff of 104%	92%	(13.3pp)	
vs. 2024 GPM		37.3%	
Soybean as % of COGS		24.5%	

Source: Goldman Sachs Global Investment Research

Exhibit 25: Beverage Monthly Tracker

	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25
Nongfu	Water yoy %	19%		down DD%	down DD%	down DD%	down strong DD%	down 5.3% (OL flat)		down DD%			down DD%	positive growth up DD%	teens%+
	Beverage yoy % (Oriental Leaf)						c.50%	c.50%	down to below 50%	down to 20%+					
	Water : green water portion %							30.20%	31.20%						
	Water AC Nielsen market														
	Overall yoy %							down DD%	down 18%	up nearly 10%	up 13%	decline	down DD%		up teens%
CR Bev	Water yoy %													up 12%	
	Beverage yoy %													up 50%	
Tingyi	Beverage sales yoy %							down SD%	down SD%	positive growth down	positive growth down	positive growth		minor positive growth	SD% decline
	Noodles sales yoy %							down LSD%	down LSD%	positive growth down	positive growth down	positive growth		minor positive growth	SD% decline
UPC	Beverage sales yoy %	up DD%	up DD%		up MSD-HSD%	up MSD-HSD%	up LSD%	up MSD%	up low teens%	up low teens%	up DD%	up DD%	up SD%	up DD%	positive growth positive growth
	Noodles sales yoy %	up SD%	up SD%			down SD%	down LSD%	flattish	up LSD%	up LSD%	up MSD-HSD%	up DD%		up DD%	
Eastroc	Overall yoy %	46% yoy	28% yoy	32% yoy	38% yoy	40%+ yoy	30%+ yoy		25% yoy		35%+ yoy	85% yoy	18% yoy	15% yoy	c.50% yoy
															30%+ yoy

Source: Channel Checks, Goldman Sachs Global Investment Research

Exhibit 26: Snacks e-commerce tracker

Company (Brand) GMV yo growth	Mar-25	Feb-25	Jan-25 + Dec 24	Jan-25	Dec-24	2024	4Q24	3Q24	2Q24	1Q24	4Q23	3Q23	2Q23	1Q23
	Douyin	Douyin	Douyin	Douyin	Douyin	Douyin	Douyin	Douyin	Douyin	Douyin	Tmall+taobao	Tmall+taobao	Tmall+taobao	Tmall+taobao
Yankershop	-4%	53%	-12%	-17%	4%	70%	18%	57%	81%	137%	-2%	41%	82%	96%
Chacha	136%	-37%	115%	133%	59%	14%	23%	-48%	-13%	123%	-29%	11%	24%	-18%
3 Squirrels	110%	65%	26%	4%	128%	132%	73%	39%	173%	357%	-32%	-8%	-23%	-50%
Ganyuan	376%	728%	-30%	-57%	191%	38%	96%	-21%	-7%	50%	-28%	18%	20%	-32%
Jinzai	61%	109%	-17%	-30%	17%	-13%	-19%	-25%	-22%	18%	-11%	15%	7%	7%
Bestore	-14%	-49%	17%	48%	-33%	29%	-15%	-6%	92%	115%	-48%	-20%	-29%	-31%

Source: Chammama, Moojing

Exhibit 27: Frozen food monthly tracker by GSE

Company	Jan-24	Feb-24	Mar-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Mar-25
Ligao	High DD	Jan + Feb 20%+	Slowdown MoM, 1Q high teens - 20%	Similar to 2Q trend, slight improvement mom	Broadly similar as before	Broadly similar as before	Encouraging recovery and look for DD% in 4Q			Flattish; +10% post LNY	Double digit yoy
Qianweiyangchu	high DD	Jan + Feb 20%+	Accelerating growth in Jul but mainly on shipment schedule		3Q: direct sales down SD% while distributor at positive yoy	Similar to 3Q trend	No significant recovery	4Q and 1Q under yoy pressure		Still soft	

Source: Channel checks, Goldman Sachs Global Investment Research

TP and estimate changes

Eastroc: Reported 1Q25 results, and we factor in the latest results. We revise up 2025-27E earnings estimates by c.3% on avg on better-than-expected electrolyte water sales momentum and better GPM. We are Buy rated with a 12-month TP of Rmb293 (vs. Rmb286 prior on higher earnings estimates), based on 30X 2026E P/E (unchanged) discounted back to end-2025E at 8.9% COE (unchanged).

Fen Wine: We factor in some more selling expenses in 2025E/26E amid the ramp-up of Fenxiangliyu, with reference to management's expectation on channel investments. We trim net profit by c.2% in 2025-26E, and our 12m TP is updated to Rmb234 (from Rmb238), with no other assumption changes. Maintain Buy.

King's Luck: We trimmed the sales volume to reflect the overall industry demand in Jiangsu, and topline/NP are lowered by up to c.2% in 2025-26E. Our 12m TP is updated to Rmb43.5 (from Rmb44.5) on our estimate revisions. Valuation multiple/COE and methodology unchanged. Maintain Neutral.

Mengniu: With reference to the YTD supply/demand trends observed by management,

we factored in higher raw milk powder impairment losses for 2025, and updated dairy farm subsidiaries' performance expectation accordingly, and therefore we lower the headline NP by 1-5% in 2025E-27E. We lowered our 12m TP to HK\$23.0 (from HK\$24.0) with the above revisions (valuation multiple/COE and methodology unchanged). Maintain Buy.

Yili: We fine-tuned our GPM assumptions to incorporate continued raw milk price benefits, while also factored in higher raw milk powder inventory impairment losses in 2025E and updated subsidiaries' full-year results. Net-net, we revised up net profit by up to 2% in 2025E-27E, and our 12m TP is updated to Rmb32.3 (from Rmb31.9) with the estimate revisions (valuation multiple/COE and methodology unchanged). Maintain Buy.

Teway: We raised our 2025E-2027E NP estimates by 1.5%~4.0% mainly on in-line sales and better-than-expected GPM from cost benefits; our TP is now Rmb10.6/sh vs. Rmb10.2/sh prior (up 4%, on higher earnings estimates), still based on 16x 2026E P/E (unchanged), discounted back to 2025 at 9.5% COE (unchanged).

Fuling: We fine-tuned our 2025E-2027E NP estimates by down 2.9% ~up 1.4%; on better sales outlook but pricing pressure on margins with more promotions; as well as factoring more admin expenses. Our TP is now Rmb11.9 vs. Rmb12 prior (down 1% on lowered earnings estimates), still based on 16x 2026E P/E discounted back to 2025 at 7.5% COE.

We also fine-tuned our estimates for Moutai for 2025-2027 factoring in 4Q results and 2025 outlook (while maintaining its TP unchanged), and adjusted quarterly growth rates for 2025 for Shanghai Bairun (while maintaining its full-year estimates and TP unchanged).

Exhibit 28: Summary of TP changes

Company	Ticker	Old Rating	Rating	Market Cap (US\$m)	Share Price 04/11/25	Ccy	Old TP	New TP	TP Chg	+/-% new TP	Trading P/E			TP implied P/E			2024e-26e CAGR (Old)		2024e-26e CAGR (Old)		Div yield 2025E
											2024e	2025e	2026e	2024e	2025e	2026e	Sales	NP	Sales	NP	
China Spirits																					
Fen Wine	600809.SS	Buy	Buy	35,925	CNY	220.99	238.00	234.00	-2%	6%	22X	21X	19X	23X	22X	20X	9.3%	9.0%	9.3%	9.9%	2.5%
King's Luck	603369.SS	Neutral	Neutral	8,744	CNY	51.74	44.50	43.50	-2%	-16%	18X	17X	15X	15X	14X	13X	9.2%	9.4%	10.1%	10.4%	2.5%
China Dairy																					
Mengniu Dairy	2319.HK	Buy	Buy	10,137	HKD	19.68	24.00	23.00	-4%	17%	n.m.	14X	12X	n.m.	17X	14X	2.6%	6.7%	2.6%	7.5%	2.8%
Yili Industrial	600887.SS	Buy	Buy	25,707	CNY	29.25	31.90	32.30	1%	10%	19X	17X	16X	21X	19X	17X	2.8%	10.0%	2.8%	8.2%	4.2%
China Condiments																					
Fuling Zhacai	002507.SZ	Neutral	Neutral	2,152	CNY	13.31	12.00	11.90	-1%	-11%	19X	18X	17X	17X	16X	15X	6.1%	7.3%	5.2%	6.2%	3.3%
Sichuan Teway	603317.SS	Sell	Sell	2,112	CNY	14.06	10.20	10.60	4%	-25%	24X	22X	19X	18X	16X	15X	7.1%	11.2%	7.1%	9.0%	3.2%
China F&B																					
Eastric Beverage	605499.SS	Buy	Buy	19,024	CNY	255.22	286.00	293.00	2%	15%	40X	30X	24X	46X	34X	28X	24.5%	28.9%	24.3%	27.3%	2.2%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 29: Summary of earnings estimate changes


Company	Revenue changes						NI changes			Revenue (mn, new)	2024e	2025e	2026e	2027e	2024e	2025e	2026e	2027e	Revenue (mn, old)			Net Income (Rmb mn, old)		
	2024e	2025e	2026e	2027e	2024e	2025e	2026e	2027e	2024e															
China Spirits																								
Kweichow Moutai	0.0%	0.2%	0.2%	0.4%	0.0%	-0.2%	0.0%	0.1%	174,144	189,458	206,702	226,326	86,228	94,978	104,681	116,414	174,144	189,102	206,213	225,457	86,228	95,139	104,704	116,321
Fen Wine	0.0%	0.0%	0.0%	0.0%	-0.0%	-0.0%	-1.7%	-1.4%	36,134	39,123	43,158	46,806	12,159	12,949	14,441	15,832	36,134	39,123	43,158	46,806	12,159	13,227	14,441	16,060
King's Luck	-0.6%	-2.3%	-2.4%	-2.4%	-0.6%	-2.2%	-2.3%	-2.3%	11,764	12,766	14,039	15,247	3,600	3,933	4,311	4,705	11,856	13,093	14,378	15,616	3,620	4,022	4,410	4,814
China Dairy	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-1.4%	-1.0%	88,675	89,934	93,315	96,763	5,602	5,844	6,380	7,098	88,675	89,934	93,315	96,763	5,602	5,843	6,473	7,169
Mengniu Dairy	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-1.4%	-1.0%	2,387	2,539	2,686	2,858	799	864	920	983	2,408	2,531	2,667	2,821	824	889	930	970
Yili Industrial	-0.5%	-0.4%	-0.4%	-0.3%	-2.0%	0.3%	1.3%	2.0%	116,452	119,998	123,084	126,787	9,777	10,845	11,838	12,755	117,089	120,503	123,632	127,146	9,976	10,814	11,685	12,507
China Condiments																								
Fuling Zhacai	-0.9%	0.3%	0.7%	1.3%	-3.0%	-2.8%	-1.0%	1.4%	2,387	2,539	2,686	2,858	799	864	920	983	2,408	2,531	2,667	2,821	824	889	930	970
Sichuan Teway	0.0%	0.0%	-0.1%	-0.1%	-0.2%	1.5%	3.9%	4.0%	3,476	3,736	3,986	4,253	625	693	772	841	3,476	3,738	3,989	4,257	626	683	743	808
China F&B																								
Eastric	0.0%	0.3%	0.3%	0.0%	2.7%	2.6%	2.6%	2.6%	15,839	20,350	24,556	28,993	3,327	4,459	5,531	6,636	15,839	20,298	24,487	28,904	3,327	4,344	5,391	6,470

Source: Company data, Goldman Sachs Global Investment Research

Valuation Analysis

Exhibit 30: Share price performance: Last week to date (Apr 4 - Apr 11) vs. YTD by consumer staples category

YTD and last week to date share price performance



Source: Refinitiv Eikon

Exhibit 31: Valuation comp sheet for China consumer staples

Company	Rating	Mkt cap US\$ mn	Ccy	Price 4/15/2025	12-m TP	+/-	PE	TP Implied PE	24-26E Rev CAGR	24-26E NP CAGR	EV/EBITDA	ROE 2025E	Div yield 2025E	YTD perf %	LST week perf %	
Spirits																
60019 SS	Kweichow Moutai	Buy	267,590	CNY	1558.00	2017.00	29%	23X	21X	19X	29X	27X	24X	9%	10%	
000686 SZ	Wuliangye Yibin	Buy	69,709	CNY	131.35	166.00	26%	16X	15X	14X	21X	19X	18X	7%	8%	
6979.HK	ZJLD	Buy	2,719	HKD	6.77	8.08	19%	12X	13X	12X	15X	15X	14X	2%	5%	
600809.SS	Shanxi Xinghuacun Fen Wine	Buy	35,925	CNY	215.36	234.00	9%	22X	20X	18X	23X	22X	20X	9%	9%	
000568.SZ	Luohu Leojing	Buy	26,077	CNY	130.21	151.00	16%	14X	14X	12X	17X	16X	14X	5%	7%	
002304.SZ	Jiangsu Yanghe	Sell	15,134	CNY	73.45	60.00	-18%	14X	14X	14X	12X	12X	11X	1%	2%	
000596.SZ	Anhui Gujing Distillery Co.	Neutral	12,431	CNY	172.00	184.00	7%	16X	15X	13X	18X	16X	14X	9%	11%	
000799.SZ	Jiugui Liquor	Sell	2,016	CNY	45.38	27.20	-40%	n.m.	53X	28X	n.m.	32X	17X	29%	n.m.	
600779.SS	Sichuan Swellfln Co.	Sell	3,136	CNY	46.96	33.30	-29%	17X	16X	16X	12X	12X	11X	6%	4%	
603369.SS	Jiangsu King's Luck Brewery	Neutral	8,744	CNY	50.98	43.50	-15%	18X	16X	15X	15X	14X	13X	9%	9%	
Avg.																
Beer																
1876.HK	Budweiser APAC	Buy	14,676	HKD	8.61	9.50	10%	20X	18X	16X	22X	20X	18X	4%	13%	
0291.HK	China Resources Beer	Buy	11,502	HKD	27.50	33.50	22%	17X	16X	14X	21X	19X	18X	2%	11%	
0168.HK	Tsingtao Brewery (H)	Buy	10,216	HKD	58.65	60.00	2%	17X	15X	14X	17X	16X	14X	4%	11%	
600600.SS	Tsingtao Brewery (A)	Neutral	14,496	CNY	78.48	68.00	-13%	25X	22X	20X	21X	19X	17X	4%	11%	
600132.SS	Chongqing Brewery	Neutral	3,903	CNY	58.98	51.50	-13%	26X	21X	20X	22X	19X	17X	3%	8%	
002568.SZ	Shanghai Bairui	Neutral	3,661	CNY	25.50	17.70	-31%	39X	32X	28X	27X	22X	19X	13%	20%	
Avg.																
Condiment																
600872.SS	Jonree Hi-Tech	Neutral	2,293	CNY	21.35	17.00	-20%	25X	21X	18X	20X	17X	14X	3%	1%	
002507.SZ	Fulin Zhaicai	Neutral	2,152	CNY	13.64	11.90	-13%	20X	18X	17X	17X	16X	15X	6%	7%	
1579.HK	Yihai International Holding	Neutral	1,674	HKD	13.38	14.20	6%	16X	14X	13X	17X	15X	14X	7%	13%	
600505.SS	Jiangsu Hengshun Vinegar	Sell	1,175	CNY	7.72	5.70	-26%	58X	43X	35X	43X	32X	26X	10%	29%	
603027.SS	Qianhe Condiment and Food	Sell	1,599	CNY	11.38	8.50	-25%	24X	22X	19X	18X	16X	15X	8%	10%	
603317.SS	Sichuan Teway Food Group	Sell	2,112	CNY	14.63	10.60	-28%	25X	22X	20X	18X	16X	15X	7%	11%	
Avg.																
Dairy																
600887.SS	Yili Industrial	Buy	25,707	CNY	29.38	32.30	10%	19X	17X	16X	21X	19X	17X	3%	10%	
2319.HK	Mengniu Dairy	Buy	10,137	HKD	19.98	23.00	15%	n.m.	14X	12X	12X	17X	14X	12X	3%	2%
6188.HK	China Felie Ltd.	Buy	7,355	HKD	6.38	7.40	16%	13X	12X	11X	15X	13X	12X	6%	5%	
Avg.																
F&B																
9633.HK	Nongfu Spring	Buy	53,866	HKD	37.15	36.30	-2%	32X	29X	26X	31X	28X	25X	14%	12%	
0322.HK	Tingyi	Buy	9,992	HKD	13.76	14.40	5%	19X	17X	15X	20X	18X	15X	3%	15%	
0220.HK	Uni-President China	Neutral	5,068	HKD	9.10	8.20	-10%	20X	17X	16X	18X	16X	14X	6%	12%	
605499.SS	Eastroc Beverage	Buy	19,624	CNY	267.58	293.00	9%	42X	31X	25X	46X	34X	28X	25%	29%	
2460.HK	China Resources Beverage	Buy	4,444	HKD	14.68	19.00	29%	17X	16X	13X	22X	20X	17X	8%	22%	
Avg.																
Snacks																
002557.SZ	Chacha Food Co.	Sell	1,877	CNY	27.17	23.20	-15%	16X	16X	15X	14X	14X	12X	6%	5%	
002847.SZ	Yankershop Food	Buy	3,239	CNY	86.32	69.10	-20%	37X	29X	26X	29X	23X	21X	17%	30%	
0151.HK	Want Want China	Sell	7,736	HKD	5.05	3.40	-33%	14X	14X	14X	9X	10X	10X	3%	0%	
300783.SZ	Three Squirrels	Neutral	1,682	CNY	30.68	31.30	2%	30X	27X	20X	31X	28X	21X	30%	21%	
Avg.																
Frozen Food																
001215.SZ	Qianweiyangchu	Neutral	338	CNY	28.54	23.20	-19%	22X	19X	17X	18X	16X	14X	7%	13%	
300973.SZ	Ligao Foods	Buy	1,027	CNY	44.37	39.60	-11%	27X	24X	17X	24X	21X	15X	15%	26%	
605089.SS	Weizixiang	Sell	462	CNY	24.47	13.60	-44%	40X	37X	33X	22X	20X	18X	5%	10%	
002216.SZ	Sanquan Foods	Neutral	1,458	CNY	12.13	8.50	-30%	21X	22X	20X	15X	15X	14X	2%	2%	
600298.SS	Angel Yeast	Buy	3,958	CNY	33.32	39.90	20%	21X	18X	15X	25X	21X	18X	10%	16%	
Avg.																
Pet Care																
002891.SZ	China Pet Foods	Buy	1,832	CNY	45.56	42.00	-8%	35X	32X	24X	32X	29X	22X	14%	21%	
300673.SZ	Petpal Pet Nutrition Technology	Neutral	507	CNY	14.62	16.60	14%	20X	19X	15X	22X	21X	16X	19%	17%	
301498.SZ	Gambol Pet Group Co.	Buy	5,324	CNY	97.33	96.00	-1%	63X	52X	41X	62X	51X	41X	20%	24%	
Avg.																

Source: Goldman Sachs Global Investment Research

Results Calendar

Exhibit 32: Earnings calendar - April

2025 APRIL							
Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	
			01 Kweichow Moutai (FY24) Chongqing Brewery (FY24)	02		03	04
06	07	08 Jonjee (FY24)	09 Angel Yeast (FY24)	10	11	12	
13	14 Qianhe (FY24&1Q) Eastroc (1Q)	15	16	17 Petpal (FY24&1Q)	18	19	
20	21 Gambol (FY24&1Q) Sanquan (FY24&1Q) Hengshun Vinegar (FY24&1Q)	22 Yankershop Food (FY24&1Q)	23 Chacha Food (FY24&1Q) China Pet Food (FY24&1Q)	24 Qianweiyangshu (FY24&1Q) Wuliangye Yibin (FY24&1Q) Fuling Zhacai (1Q) Angel Yeast (1Q)	25	26	
27 Gujing (FY24&1Q) Luzhou Laojiao (FY24&1Q)	28 Weizhixiang (FY24&1Q) Ligao Food (FY24&1Q) Shanghai Bairun (FY24&1Q) Jiugui Liquor (FY24&1Q) Jiangsu Yanghe (FY24&1Q) Sichuan Teway (1Q) Three Squirrels (1Q) Tsingtao Brewery (1Q)	29 Yili (FY24&1Q) Fen Wine (FY24&1Q) Swellfun (FY24&1Q) King's Luck (FY24&1Q) Chongqing Brewery (1Q) Jonjee Hi-Tech (1Q) Kweichow Moutai (1Q)	30				

Source: Company data, Goldman Sachs Global Investment Research

Valuation methodology and risks

Exhibit 33: Valuation Methodology and Key Risks- Spirits

Ticker	Company	Valuation Methodology	Key Risks
600519.SS	Kweichow Moutai	Our 12-m TP is based on 26.5x 2026E P/E discounted back to end-2025E using a 9.5% COE	Downside: 1) Potential regulation changes such as a consumption tax rate hike; 2) Environmental pollution; 3) A slower-than-expected macroeconomic recovery; 4) Capacity constraints; 5) More volatility in US rate hikes given the negative correlation between Moutai's P/E and the US 10-yr bond yield.
000858.SZ	Wuliangye Yibin	Our 12-m TP is based on 19.5x 2026E P/E discounted back to end-2025E using a 10.3% COE	Downside: 1) Potential Consumption tax rate hike, 2) Potential threats from Moutai-flavor brands, 3) Intensifying competition in high-end spirits.
6979.HK	ZJLD	Our 12-m TP is based on 14.5x 2026E P/E discounted back to end-2025E using an 8.2% COE	Downside: 1) Regulations risks on spirits sector may have adverse business impacts; 2) Intensified competition may deteriorate profitability; 3) Macroeconomic and industry uncertainties may lead to channel destocking and decrease in wholesale prices; 4) Environmental pollution of key production regions and potential natural disasters may impose business risks; 5) Potential conflict of interests.
600809.SS	Shanxi Xinghuacun Fen Wine	Our 12-m TP is based on 21.8x 2026E P/E discounted back to end-2025E using an 10.3% COE	Downside: 1) Consumption tax reform, 2) Economic slowdown.
000568.SZ	Luzhou Laojiao	Our 12-m TP is based on 15.6x 2026E P/E discounted back to end-2025E using a 8.4% COE	Downside: 1) Potential Consumption tax rate hike, 2) Potential threats from Moutai-flavor brands, 3) Intensifying competition in high-end spirits.
000596.SZ	Anhui Gujing Distillery Co.	Our 12-m TP is based on 15.5x 2026E P/E discounted back to end-2025E using an 8.3% COE	Downside: 1) Higher-than expected competition in Anhui province, 2) Further economic slowdown, 3) Greater channel inventory amid weaker retail sell-through. Upside: 1) Stronger-than-expected management execution for national expansion, 2) Better-than-expected product upgrade
603369.SS	Jiangsu King's Luck Brewery	Our 12-m TP is based on 14.0x 2026E P/E discounted back to end-2025E using a 10.6% COE	Upside: 1) Better-than-expected competitive landscape in Jiangsu province; 2) Stronger-than-expected management execution for national expansion; 3) Better-than-expected product upgrade Downside: 1) More intensified competition/ worsened demand in Jiangsu; 2) Weaker distributors' confidence and channel inventory situation
002304.SZ	Jiangsu Yanghe	Our 12-m TP is based on 12.4x 2026E P/E discounted back to end-2025E using a 10.8% COE	Upside: 1) Stronger-than-expected policy stimulus execution; 2) Better-than-expected competitive landscape in Jiangsu province; 3) Stronger-than-expected performance outside Jiangsu province
000799.SZ	Jiugui Liquor Co.	Our 12-m TP is based on 19.3x 2026E P/E discounted back to end-2025E using a 13.2% COE	Upside: 1) Significant improvement on channel inventory level; 2) Stabilization of wholesale prices, especially Neican; 3) Better-than-expected commercial banquet demand recovery.
600779.SS	Sichuan Swellfun Co.	Our 12-m TP is based on 12.4x 2026E P/E discounted back to end-2025E using an 11.5% COE	Upside: 1) Expansion of Diancang series, 2) Faster than expected penetration of Tianhaochen in the mass market, 3) Better than expected inventory digestion

Source: Goldman Sachs Global Investment Research

Exhibit 34: Valuation Methodology and Key Risks- Beer

Ticker	Company	Valuation Methodology	Key Risks
0291.HK	China Resources Beer	19.0x 2026E P/E, in line with global peers' full cycle average in the last five years, discounted back to end-2025E using a 10.1% COE	1) Slower-than-expected premium volume growth; 2) Intense competition in the premium segment; 3) Higher-than-expected cost pressure.
1876.HK	Budweiser APAC	19.0x 2026E P/E, in line with global peers' full cycle average in the last five years, discounted back to end-2025E using a 8.8% COE	1) Weaker-than-expected premium channel recovery; 2) More intense China competition; 3) Cost inflation.
0168.HK	Tsingtao Brewery - H	15.2X 2026E P/E, in line with global peers' full cycle avg in the past 5 years applying a historical average of A-H premium at 25%, discounted back to end-2025E using a 9.6% COE	1) Slower-than-expected premium volume growth; 2) Intense competition from higher marketing and channel investments by peers; 3) Unsuccessful national scale price hikes.
600600.SS	Tsingtao Brewery - A	19.0x 2026E P/E, in line with global peers' full cycle average in the last five years, discounted back to end-2025E using a 9.9% COE	1) Slower-/faster-than-expected premium volume growth; 2) Intense competition from higher marketing and channel investments by peers; 3) Successful/unsuccessful national scale price hikes.
600132.SS	Chongqing Brewery	19.0x 2026E P/E, in line with global peers' full cycle average in the last five, discounted back to end-2025E using a 10.8% COE	1) Slower-/faster-than-expected Wusu brand growth; 2) Higher ASP increase; 3) Unfavorable cost trend.
002568.SZ	Shanghai Bairun	21.0x 2026E P/E with reference to the last FY's average trading P/E, discounted back to end-2025E using a 9.9% COE	Faster/slower demand growth, more/less intense competition, higher/lower-than-expected selling expense, raw material risk.

Source: Goldman Sachs Global Investment Research

Exhibit 35: Valuation Methodology and Key Risks- F&B and Dairy

F&B	Company	Valuation methodology	Risks
9633.HK	Nongfu Spring	Our 12-m TP is based on 25X 2026E P/E in line with global peers in the past five years, discounted back to 2025 year-end using an 8.7% COE	Key risks: 1) Lower-than-expected tea/water sales momentum; 2) Higher-than-expected cost inflation; 3) More intense beverage industry competition.
0322.HK	Tingyi	Our 12-m TP is based on a 15X 2026E P/E based on the average of past 2 year P/E of Tingyi/UPC, discounted back to 2025 year-end using an 7.7% COE	Key risks: 1) Higher-than-expected raw material cost pressures; weaker premiumization trends in instant noodle/beverage.
0220.HK	Uni-President China	Our 12-m TP is based on a 15X 2026E P/E based on the average of past 2 year P/E of Tingyi/UPC, discounted back to 2025 year-end using an 8.1% COE	Key risks: 1) Higher-than-expected raw material cost pressures; 2) more intense competition in instant noodles/beverage; 3) food quality issue.
605499.SS	Eastroc	Our 12-m TP is based on a 30X 2026E P/E discounted back to end-2025E using an 8.9% COE, with reference to historical average P/E of Monster Beverage in 2017-2019 when Red Bull was losing share in the US	Key risks: 1) Lower industry growth in energy drinks, 2) worse competitive landscape, 3) failure/slower ramp-up of Eastroc's new product launches, 4) potential capacity shortage with already high utilization ratio, 5) higher increases in raw material costs, 6) slower geographical expansion of Eastroc, 7) slower POS penetration/deployment of fridges, and 8) reputational risks.
2460.HK	CR Beverage	Our 12-m TP is based on a 15X 2026E P/E based on a 19.0x 2025E P/E referring to the avg. P/E of Tingyi/UPC during 2018-2024YTD given similar growth stages.	Key risks: 1) More intensified competition than expected in the bottled water market; 2) Slower than expected development of the beverage business; 3) Raw material price movements; 4) Uncertainty over channel/distribution management; 5) Reputational risks/ food security issues.
Dairy	Company	Valuation methodology	Risks
600887.SS	Yili	Our 12-month TP is based on 2026E P/E of 18.9x (20% A/H premium to the target level of 1STD below prior downcycle P/E in 2015-16), discounted back to 2025 year-end using an 8.8% COE	Key risks: Slower-than-expected liquid milk premium demand, slower dairy demand recovery, more intense competition
2319.HK	Mengniu	Our 12-month TP is based on 2026E P/E of 15.1x (1STD below prior downcycle P/E in 2015-16), discounted back to 2025 year-end using a 9.6% COE	Key risks: Slower-than-expected premium demand, slower than expected dairy demand recovery, more intense dairy industry competition, wider losses in new categories.
6186.HK	Feihe	Our 12-m TP is based on an 9x 2026E P/E (55% discount to 1 STD below the historical 5-year avg. P/E of global IMF names), discounted back to 2025 year-end using an 11.3% COE	Key risks: 1) lower-than-expected new birth rates; 2) more intense competition; 3) slower premium segment growth; 4) industry-wide food safety issues; 5) lower-than-expected incremental policy support.

Source: Goldman Sachs Global Investment Research

Exhibit 36: Valuation Methodology and Key Risks- Condiments

Ticker	Company	Valuation Methodology	Key Risks
002507.SZ	Fuling Zhacai	16x P/E applied to 2026E avg. EPS, which is broadly in line with US peers' trading P/E in the downturn around 2018 when facing private-label competition, discounted back to 2025YE using 7.5% COE	Downside/upside risks: 1) Better/worse-than-expected demand recovery, amid the current consumption backdrop; 2) Slower/faster expansion into new products/categories: Fuling has attempted to diversify its product portfolio and allocate resources to developing products aside from its main sales driver Zhacai; 3) Slower/faster expansion into channels & more/less efficient use of expenses
600872.SS	Jonjee Hi-Tech	16x P/E applied to 2026E avg. EPS, which is broadly in line with US peers' trading P/E in the downturn around 2018 when facing private-label competition, discounted back to 2025YE using 10.3% COE	1) Faster-/slower-than-expected distributor recruitment; 2) More/less efficient and targeted channel investments; 3) Better-/worse-than-expected consumer demand recovery and mix; 4) Better-/worse-than-expected margin from internal changes in operation efficiency; 5) Better-/worse than expected competition landscape in the soy sauce market.
603027.SS	Qianhe Condiment and Food	16x P/E applied to 2026E avg. EPS, which is broadly in line with US peers' trading P/E in the downturn around 2018 when facing private-label competition, discounted back to 2025YE using 9.9% COE	Upside risks: 1) Higher margin on expansion of high-end product lines; 2) Margin improvement on cost deflation; 3) Penetration increase in wholesale channels; 4) More efficient marketing investments
600305.SS	Jiangsu Hengshun Vinegar	32x P/E applied to 2025E avg. EPS, on SOE reform potential benefits	Upside risks: 1) Stronger-than-expected volume growth, 2) Better-than-expected return from enhanced marketing investment.
1579.HK	Yihai International Holding	15x P/E applied to 2026E avg. EPS discounted back to 2025YE using 12.0% COE	Downside risks: 1) Intensifying competition in the compound condiments market; and 2) a further slowdown in related party sales.
603317.SS	Sichuan Teway Food Group	16x P/E applied to 2026E avg. EPS, which is broadly in line with US peers' trading P/E in the downturn around 2018 when facing private-label competition, discounted back to 2025YE using 9.5% COE	Upside risks: 1) Utilization ramp-up; 2) More efficient brand building; 3) Penetration into 2B markets. Downside risk: 1) Cost pressure weighs on margins.

Source: Goldman Sachs Global Investment Research

Exhibit 37: Valuation Methodology and Key Risks - Prepared food, Snacks, Pet

Ticker	Company	Valuation Methodology	Risks
Prepared food			
300973.SZ	Ligao Foods	Our Price Target is based on 16x P/E applied to 2026E EPS discounted back 1 year at COE 8.4%.	Key downside risks: 1) Weaker-than-expected fresh bakery recovery; 2) Weaker-than-expected KA client sales; 3) Shareholding reduction by major shareholders; 4) Raw material costs; and 5) Intensifying competition in the frozen bakery market; 6) Food safety.
001215.SZ	Qianweiyangchu	Our Price Target is based on 15.1x P/E applied to 2026E EPS discounted back 1 year at COE 8.6%.	Key upside risks: 1) more SKUs supplied to top clients; 2) faster-than-expected pace of new clients development; 3) easing competition; Key downside risks: 1) top client (e.g. YUMC) concentration risks; 2) related party risks; 3) food safety
002216.SZ	Sanquan Foods	Our Price Target is based on 15.1x P/E applied to 2026E EPS discounted back 1 year at COE 8.6%.	Key risks: 1) higher/lower than expected foodservice channel growth; 2) higher/lower than expected performances of new products; 3) raw material costs; 4) shareholding structure; and 5) food safety.
605089.SS	Weizhixiang	Our Price Target is based on 20x P/E applied to 2026E EPS discounted back 1 year at COE 9.3%.	Key upside risks: 1) Successful store rollout in new regions; 2) Better aligned management incentives; 3) Easier competitive landscape; and 4) Raw material costs.
600298.SS	Angel Yeast	Our 12-month TP is based on a 20X P/E applied to our 2026E EPS, discounted back 1 year at 8.1% COE.	Key downside risks: 1) Faster-than-expected capacity expansion pace leading to oversupply pressure on pricing/sales; 2) Cost headwinds leading to margin contraction; 3) Worse-than-expected baking yeast demand in the domestic market.
Snacks			
002847.SZ	Yankershop	Our 12-m TP is based on a 22x P/E and 2026E EPS discounted back 1 year to 2025 end at a COE of 7.0%.	Key risks: More intense competition in the snacking industry; snack discounters roll-out private label products; higher-than-expected raw material cost; slower distributor expansion
002557.SZ	Chacha food	Our 12-m TP is based on a 13X P/E on our 2026E EPS discounted back 1 year to 2025 end at a COE of 7.1%.	Key upside risks: 1) Downstream demand is less value-focus; 2) Successful launch of new blockbuster SKUs; 3) Faster-than-expected margin improvement on cost deflation
0151.HK	Wang Want China	Our 12-m TP is based on a 10X P/E on our 2026E EPS discounted back 1 year to 2025 end at a COE of 5.8%.	Key upside risks: Better-than-expected dairy recovery, faster-than-expected new products/channel sales contribution, stronger margin recovery from favorable costs.
300783.SZ	Three Squirrels	Our 12-m TP is based on a 24x 2026E P/E discounted back to 2025E at 7.6% COE.	Key risks: 1) More effective/ineffective initiatives for reviving offline channel; 2) Faster/slower-than-expected ramping up of capacity; 3) Larger-than-expected raw material prices tailwind/headwind.
Pet food			
002891.SZ	China Pet	Our 12m SOTP-based target price is based on 18X FY25E P/E for the overseas business and 26X FY27E P/E for the domestic business discounted back 2 years at 7.9% COE.	Key downside risks: Slower than expected domestic revenue growth, food safety issues, fluctuation in exchange rates, and freight and raw material costs.
300673.SZ	Petpal	Our 12-m TP is based on SOTP, with 16X FY25E P/E for the overseas business and 26X FY26E P/E discounted back 1 year with 6.9% COE for the domestic business.	Key risks: More/less intense competition in the overseas business; risks of order change/receivable collection from large clients; better-/worse-than-expected execution of domestic brand building and channel expansion.
301498.SZ	Gambol Pet	Our 12m TP is based on a SOTP, with 1) the domestic business valued at a 37X 2027E P/E discounted back to end-2025 at a 7.0% COE, and 2) the overseas business at 18X P/E on 2025E earnings.	Downside risks: Food safety issues; stock overhang from pre-IPO investors' exit; overseas: fluctuation of exchange rates, freight and input prices, potential tariff on export.

Source: Goldman Sachs Global Investment Research

Disclosure Appendix

Reg AC

We, Leaf Liu, Valerie Zhou, Hongda Zhong, Julia Mu and Christina Liu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACP) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Angel Yeast, Anhui Gujing Distillery Co., Budweiser APAC, Chacha Food Co., China Feihe Ltd., China Pet Foods, China Resources Beer, Chongqing Brewery, Eastroc Beverage, Foshan Haitian Flavouring & Food, Fu Jian Anjoy Foods Co., Fuling Zhacai, Jiangsu Hengshun Vinegar, Jiangsu King's Luck Brewery, Jiangsu Yanghe, Jiugui Liquor, Jonjee Hi-Tech, Kweichow Moutai, Ligao Foods, Luzhou Laojiao, Mengniu Dairy, Nongfu Spring, Petpal Pet Nutrition Technology, Qianhe Condiment and Food, Qianweiyangchu, Sanquan Foods, Shanghai Bairun, Shanxi Xinghuacun Fen Wine, Sichuan Swellfun Co., Sichuan Teway Food Group, Tingyi, Tsingtao Brewery (A), Tsingtao Brewery (H), Uni-President China, Want Want China, Weizhixiang, Wuliangye Yibin, Yankershop Food, Yihai International Holding, Yili Industrial and ZJLD is/are relative to the other companies in its/their coverage universe: Angel Yeast, Anhui Gujing Distillery Co., Budweiser APAC, Chacha Food Co., China Feihe Ltd., China Pet Foods, China Resources Beer, China Resources Beverage, Chongqing Brewery, Eastroc Beverage, Foshan Haitian Flavouring & Food, Fu Jian Anjoy Foods Co., Fuling Zhacai, Gambol Pet Group Co., Jiangsu Hengshun Vinegar, Jiangsu King's Luck Brewery, Jiangsu Yanghe, Jiugui Liquor, Jonjee Hi-Tech, Kweichow Moutai, Ligao Foods, Luzhou Laojiao, Mengniu Dairy, Nongfu Spring, Petpal Pet Nutrition Technology, Qianhe Condiment and Food, Qianweiyangchu, Sanquan Foods, Shanghai Bairun, Shanxi Xinghuacun Fen Wine, Sichuan Swellfun Co., Sichuan Teway Food Group, Three Squirrels, Tingyi, Tsingtao Brewery (A), Tsingtao Brewery (H), Uni-President China, Want Want China, Weizhixiang, Wuliangye Yibin, Yankershop Food, Yihai International Holding, Yili Industrial, ZJLD

Company-specific regulatory disclosures

Compendium report: please see disclosures at <https://www.gs.com/research/hedge.html>. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	49%	34%	17%	63%	57%	42%

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)

Compendium report: please see disclosures at <https://www.gs.com/research/hedge.html>. Disclosures applicable to the companies included in this

compendium can be found in the latest relevant published research

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.

Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

Distribution of ratings: See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <https://www.gs.com/research/hedge.html>.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: <https://publishing.gs.com/disclosures/hedge.html#/general/equity>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) 2016/958 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The

Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contato@goldmansbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Públco Goldman Sachs Brasil: 0800 727 5764 e/ou contato@goldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution and the Autorité des marchés financiers ("AMF") disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and <https://www.fiadocumentation.org/fia/regulatory-disclosures/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018>. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.